RISMA Systems (RISMA) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
9 Jul, 2026Executive summary
Annual recurring revenue (ARR) rose 33% year-over-year to 39.1 MDKK as of June 30, 2024, with H1 ARR growth of 5.2 MDKK.
Revenue increased 33% to 19.5 MDKK in H1 2024, driven by new sales and stable upselling.
Denmark is the most mature and prioritized market, with over 60% of growth originating there; Norway and Sweden follow in focus, though Swedish sales underperformed and are being reorganized.
Investments in sales and marketing increased in H1 2024 to drive future growth, with expected returns in 2025 due to long sales cycles and ramp-up periods.
RISMA launched a new DORA solution for the financial industry and plans two more launches in H2 2024, including version 10.0 of its software in late October or early November.
Financial highlights
Gross profit increased to 13.4 MDKK in H1 2024 from 9.9 MDKK in H1 2023, a rise of almost 40%.
EBITDA was -3.6 MDKK in H1 2024, slightly below -3.3 MDKK in H1 2023, but expected to improve in H2 and remain within guided range.
Net loss for H1 2024 was -5.3 MDKK, compared to -5.0 MDKK in H1 2023.
Staff costs rose to -17.0 MDKK from -13.1 MDKK year-over-year, reflecting workforce expansion.
Cash and cash equivalents stood at 10.1 MDKK as of June 30, 2024.
Outlook and guidance
ARR guidance for 2024 remains at 45–49 MDKK, expected at the lower end.
EBITDA guidance for 2024 is unchanged at -5.6 to -9.6 MDKK.
Positive impact from increased sales and marketing investments anticipated in 2025, but no specific growth guidance for 2025 provided yet.
Pipeline remains strong, with continued investment in growth initiatives.
Latest events from RISMA Systems
- ARR up 29% year-over-year to 39.2 MDKK, with 2024 guidance reaffirmed.RISMA
Q3 202413 Jun 2025 - ARR up 24% and EBITDA improved, but 2025 growth to slow due to EU CSRD changes.RISMA
Q4 20249 Jun 2025 - ARR up 23% to 43.8 MDKK, but guidance lowered due to churn and regulatory uncertainty.RISMA
Q1 20256 Jun 2025